<abstract xmlns="http://www.w3.org/1999/xhtml"> Background: Persistent pulmonary hypertension of the newborn (PPHN) is one of the most serious conditions in neonates, and has high mortality and morbidity rates. New alternative therapies have been sought for improving survival and reducing morbidity for PPHN.Objective: To report an initial experience of using intravenous iloprost to treat infants with PPHN, and assess its effect on oxygenation and hemodynamic stability over a 96-hour study.Methods: The clinical data of infants who received intravenous iloprost as first line adjunctive therapy for PPHN at our institution between March 2009 and June 2010 were retrospectively reviewed.Results: During the study period, 10 PPHN infants received intravenous iloprost as the first line of adjunctive therapy. The median gestational age was 40 weeks (range: 38-42), and birth weight was 3,250 grams (range: 2,310-3,900 g). Intravenous iloprost was initiated at an average age of 38 ± 26 hours (median: 32 h, range: 6-79 h), with an average baseline oxygen index (OI) of 25 ± 18 (median: 18, range: 8-65). Two infants who died while receiving the intravenous iloprost were excluded from our analysis because of incomplete data. Of the 8 who survived, the baseline OI was 24 ± 20 (median: 17, range: 8-65), and the mean OIs at 24 and 72 hours following treatment were significantly improved (16 ± 18 (median: 6, range: 4-50) (p = 0.02), and 9 ± 5 (median: 8, range: 3-18) (p = 0.02), respectively). No clinically significant changes in heart rate or blood pressure were noted during the iloprost therapy. At discharge, 6 of the infants were clinically normal, and 2 were complicated with cholestatic jaundice. No neurodevelopmental or cardiopulmonary disorders were observed in the 8 surviving infants at hospital discharge or later follow-up visits.Conclusion: Intravenous iloprost may be a useful adjunctive therapy in PPHN, and should be investigated in a larger controlled study.</abstract>

Background: Persistent pulmonary hypertension of the newborn (PPHN) is one of the most serious conditions in neonates, and has high mortality and morbidity rates. New alternative therapies have been sought for improving survival and reducing morbidity for PPHN.Objective: To report an initial experience of using intravenous iloprost to treat infants with PPHN, and assess its effect on oxygenation and hemodynamic stability over a 96-hour study.Methods: The clinical data of infants who received intravenous iloprost as first line adjunctive therapy for PPHN at our institution between March 2009 and June 2010 were retrospectively reviewed.Results: During the study period, 10 PPHN infants received intravenous iloprost as the first line of adjunctive therapy. The median gestational age was 40 weeks (range: 38-42), and birth weight was 3,250 grams (range: 2,310-3,900 g). Intravenous iloprost was initiated at an average age of 38 ± 26 hours (median: 32 h, range: 6-79 h), with an average baseline oxygen index (OI) of 25 ± 18 (median: 18, range: 8-65). Two infants who died while receiving the intravenous iloprost were excluded from our analysis because of incomplete data. Of the 8 who survived, the baseline OI was 24 ± 20 (median: 17, range: 8-65), and the mean OIs at 24 and 72 hours following treatment were significantly improved (16 ± 18 (median: 6, range: 4-50) (p = 0.02), and 9 ± 5 (median: 8, range: 3-18) (p = 0.02), respectively). No clinically significant changes in heart rate or blood pressure were noted during the iloprost therapy. At discharge, 6 of the infants were clinically normal, and 2 were complicated with cholestatic jaundice. No neurodevelopmental or cardiopulmonary disorders were observed in the 8 surviving infants at hospital discharge or later follow-up visits.Conclusion: Intravenous iloprost may be a useful adjunctive therapy in PPHN, and should be investigated in a larger controlled study.

Intravenous iloprost may be an effective first-line treatment for persistent pulmonary hypertension of the newborn in limited-resource situations

MD, Neonatal Intensive Care Unit, Hat Yai Medical Education Center, Hat Yai Hospital, Songkhla, 90110, Thailand

Department of Pediatrics, Hat Yai Medical Education Center, Hat Yai Hospital, Songkhla, 90110,

Department of Medicine, Hat Yai Medical Education Center, Hat Yai Hospital, Songkhla, 90110,

Asian Biomedicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Background: Persistent pulmonary hypertension of the newborn (PPHN) is one of the most serious conditions in neonates, and has high mortality and morbidity...

Intravenous iloprost may be an effective first-line treatment for persistent pulmonary hypertension of the newborn in limited-resource situations

Article Category: Brief communication (Original)

Publicado en línea: 04 feb 2017

Páginas: 873 - 880

DOI: https://doi.org/10.5372/1905-7415.0706.252

Palabras clave
Iloprost, newborn infant, neonatal mortality, persistent pulmonary hypertension of the newborn

© 2017

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Intravenous iloprost may be an effective first-line treatment for persistent pulmonary hypertension of the newborn in limited-resource situations

Article Category: Brief communication (Original)

Publicado en línea: 04 feb 2017

Páginas: 873 - 880

DOI: https://doi.org/10.5372/1905-7415.0706.252

Palabras claveIloprost, newborn infant, neonatal mortality, persistent pulmonary hypertension of the newborn

© 2017

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Palabras clave
Iloprost, newborn infant, neonatal mortality, persistent pulmonary hypertension of the newborn